Itruvone (PH10)
Major Depressive Disorder (MDD)
Key Facts
About Vistagen Therapeutics
Vistagen is advancing a novel neuroscience platform centered on pherines, which are neuroactive nasal sprays designed to modulate the olfactory-amygdala neural circuits, offering a potential rapid-onset treatment for mood and anxiety disorders without systemic exposure. Its lead candidate, fasedienol (PH94B), is in Phase 3 development for social anxiety disorder, and it has multiple other clinical-stage assets for major depressive disorder and postpartum anxiety. The company's strategy focuses on developing non-systemic, non-addictive alternatives to current standard-of-care treatments, positioning it in a high-value segment of the CNS therapeutics market.
View full company profileAbout Vistagen Therapeutics
Vistagen is advancing a novel neuroscience platform centered on pherines, which are neuroactive nasal sprays designed to modulate the olfactory-amygdala neural circuits, offering a potential rapid-onset treatment for mood and anxiety disorders without systemic exposure. Its lead candidate, fasedienol (PH94B), is in Phase 3 development for social anxiety disorder, and it has multiple other clinical-stage assets for major depressive disorder and postpartum anxiety. The company's strategy focuses on developing non-systemic, non-addictive alternatives to current standard-of-care treatments, positioning it in a high-value segment of the CNS therapeutics market.
View full company profileTherapeutic Areas
Other Major Depressive Disorder (MDD) Drugs
| Drug | Company | Phase |
|---|---|---|
| XEN1101 | Xenon Pharmaceuticals | Phase 3 |
| BHV-5000 (NMDA antagonist) | Biohaven | Phase 1 |
| Undisclosed CNS Candidate | Alto Neuroscience | Phase 1 |
| Navacaprant (NMRA-140) | Neumora Therapeutics | Phase 3 |
| MW-101 | MindWalk Holdings | Phase 2 |
| NPH-101 | Neuphoria Therapeutics | Phase 2 |